Redwood Pharma AB has entered into a licensing agreement with Broda Technologies Co., Ltd., operating in both the US and China, to use the company's proprietary IntelliGel® supramolecular hydrogel technology in its lead chronic Dry Eye therapeutic currently under development and other ophthalmic therapies. The Broda technology offers many unique competitive benefits. At lower temperatures, the polymer solution is a free-forming liquid and with low concentrations of polymer the system can be transitioned to a gel at specific temperatures. Reversible and transparent, the thermogel offers an ideal platform as a vehicle for sustaining the release of active substances, thereby reducing the total amount, as well as the number of doses administered.
Redwood Pharma will develop new ophthalmic therapies using IntelliGel. CEO Martin Vidaeus remarked, "IntelliGel offers the ability for Redwood Pharma to meet consumer needs with convenience, safety and efficacy while developing its own products, as well as helping other ophthalmic pharmaceutical companies extend their product franchises with a novel slow-release platform."
FDA strengthens AI regulation to ensure patient safety and innovation in healthcare